The most frequent
infusion-related events after initial dosages were chills and fever.
Frequency and severity of adverse events decreased in subsequent
dosing.
Warnings and
precautions for use in the treatment of diabetic patients It should
be noted that each vial of AMPHOCIL contains lactose monohydrate.
In the treatment of renal dialysis patients AMPHOCIL should be administered
only at the end of each dialysis period. Serum electrolytes, particularly
potassium and magnesium, should be regularly monitored.
Interactions
with other medicaments and other forms of interaction There have
been no reported interactions between AMPHOCIL and other drugs including
cyclosporine, However, caution should be used in patients receiving
concomitant therapy with drugs known to interact with conventional
amphotericin B such as nephrotoxic drugs (aminoglycosides, cisplatin,
and pentamidine), corticosteroids, and corticotrophin (ACTH) that
may potentiate hypokalaemia and digitalis glycosides, muscle relaxants
and antiarrhythmic agents whose effects may be potentiated in the
presence of hypokalaemia. The use of flucytosine with AMPHOCIL has
not been studied. While the synergy between amphotericin B and flucytosine
has been reported, amphotericin B may enhance the toxicity of flucytosine
by increasing its cellular uptake and impeding its renal excretion.
Pregnancy and
lactation Pregnancy Animal reproductive toxicology studies with
AMPHOCIL have shown no evidence of harm to the fetus. Although the
active ingredient, amphotericin B, has been in wide use for many
years without apparent ill consequence, there is inadequate evidence
of safety of AMPHOCIL in human pregnancy. Therefore, it is recommended
that administration of AMPHOCIL is avoided in pregnancy unless the
anticipated benefit to the patient outweighs the potential risk
to the fetus.
Nursing mothers
It is not known whether amphotericin B is excreted in human milk.
Consideration should be given to discontinuation of nursing during
treatment with AMPHOCIL.